NAN 190
Latest Information Update: 24 Aug 1998
Price :
$50 *
At a glance
- Originator Novo Nordisk
- Developer Nonindustrial source
- Class Antihypertensives; Anxiolytics; Piperazines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor antagonists; Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension; Major depressive disorder
Most Recent Events
- 24 Aug 1998 No-Development-Reported for Anxiety disorders in USA (Unknown route)
- 24 Aug 1998 No-Development-Reported for Depression in USA (Unknown route)
- 24 Aug 1998 No-Development-Reported for Hypertension in Japan (Unknown route)